Omeros Corp. (OMER), a clinical-stage biopharmaceutical company, Monday reported fourth-quarter net loss of $7.73 million or $0.30 per share, narrower than last years' loss of $10.20 million or $0.46 per share last year.
Revenues for the quarter were $1.58 million compared to $1.14 million last year.
Research and development expenses increased to $9.35 million from $8.90 million last year. General and administrative costs increased to $3.72 million from $2.10 million last year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.